Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 05, 2015 12:31 AM ET


Company Overview of Population Genetics Technologies Ltd.

Company Overview

Population Genetics Technologies Ltd. develops and patents technologies that find, characterize, and quantify true genetic variants responsible for disease, disease resistance, and drug response for agricultural biotechnology, infectious disease, and cancer markets. It provides Reflex, a method for sequencing long contiguous regions in populations of interest for the identification of genetic variants that correlate with phenotype; and VeriTag, a solution to sensitively quantify genomic variants. The company was incorporated in 2004 and is based in Cambridge, United Kingdom.

Minerva, Building 250

Babraham Research Campus


Cambridge,  CB22 3AT

United Kingdom

Founded in 2004


44 1223 497 357


44 1223 497 351

Key Executives for Population Genetics Technologies Ltd.

Chief Executive Officer and Director
Co-Founder and Executive Chairman
Age: 76
Co-Founder and Scientific Advisor
Age: 88
Co-Founder and Scientific Advisor
Chief Operating Officer and Chief Commercial Officer
Compensation as of Fiscal Year 2015.

Population Genetics Technologies Ltd. Key Developments

Population Genetics Announces Agreement with Case Western Reserve University to Develop Innovative Diagnostics Technology

Population Genetics Technologies Ltd. announced a scientific agreement with Case Western Reserve University. The company will work closely with Dr. Miguel Quinones-Mateu, Assistant Professor in the Department of Pathology and Scientific director of the University Hospitals Translational (CLIA/CAP certified) Laboratory. The focus of the research will be the further development of diagnostic tests to determine HIV drug resistance for use in clinical management of HIV positive patients.

Population Genetics Licenses VeriTag Patent to Agilent Technologies

Population Genetics Technologies Ltd. (PGT) has exclusively licensed patent rights including US 8,481,292 covering its VeriTag technology to Agilent Technologies. PGT retains exclusive rights to develop and commercialize VeriTag for applications in human infectious disease diagnostics, and non-exclusive rights for veterinary diagnostics and plant genomic uses. VeriTag is a PGT proprietary technology which allows for the sensitive and confident detection of minority genetic variants on next generation sequencing platforms to levels below 0.1%.

Similar Private Companies By Industry

Company Name Region
Oxford BioTherapeutics Limited Europe
Proximagen Group plc Europe
Videregen Limited Europe
Epsom Glass Industries Limited Europe
MGB Biopharma Limited Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Population Genetics Technologies Ltd., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at